What is William Blair’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Stock analysts at William Blair issued their Q1 2025 EPS estimates for shares of FibroGen in a research report issued on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $24.91 million.

Several other equities analysts have also issued reports on FGEN. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of FibroGen in a report on Tuesday. StockNews.com started coverage on FibroGen in a research note on Friday, March 14th. They issued a “hold” rating for the company.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.32 on Thursday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80. The stock has a market cap of $31.74 million, a P/E ratio of -0.26 and a beta of 0.82. The firm has a 50 day moving average price of $0.49 and a 200 day moving average price of $0.43.

Institutional Investors Weigh In On FibroGen

Several large investors have recently made changes to their positions in FGEN. JPMorgan Chase & Co. increased its holdings in FibroGen by 430.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares in the last quarter. Mackenzie Financial Corp raised its position in FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 441,083 shares during the last quarter. Squarepoint Ops LLC bought a new stake in FibroGen in the 4th quarter valued at approximately $205,000. Finally, Two Sigma Advisers LP boosted its position in FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after acquiring an additional 135,600 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.